COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

7.630 +1.820 (+31.33%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD ↗

March 01, 2024

The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.

Via Talk Markets

Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript ↗

February 29, 2024

CMPS earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment ↗

February 29, 2024

Via Benzinga

Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream' ↗

February 29, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Preview For Compass Pathways ↗

February 28, 2024

Via Benzinga

Penny Power Players: 3 Stocks to Watch in the Microcap Arena ↗

February 27, 2024

Dive into three microcap stocks set to skyrocket with innovative strategies and sector leadership. Don't miss out.

Via InvestorPlace

Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America? ↗

February 02, 2024

Via Benzinga

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 29, 2024

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Via Benzinga

Mental Health Mavericks: 3 Stocks Changing the Game ↗

February 21, 2024

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Via InvestorPlace

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen. ↗

February 19, 2024

The lofty target is closer to being within reach than it may seem at first.

Via The Motley Fool

Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex ↗

February 18, 2024

IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...

Via Talk Markets

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Why Is MindMed (MNMD) Stock Up 8% Today? ↗

February 12, 2024

MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.

Via InvestorPlace

5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week ↗

January 30, 2024

The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.

Via Talk Markets

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy ↗

January 25, 2024

Study found that suggestibility did not predict response to psilocybin therapy for MDD patients, challenging concerns about placebo effects.

Via Benzinga

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗

January 15, 2024

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.

Via Benzinga

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

January 24, 2024

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

Via FinancialNewsMedia

5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week ↗

January 13, 2024

The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.

Via Talk Markets

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution ↗

January 09, 2024

Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024.

Via InvestorPlace

3 Big New Catalysts for Psychedelics Stocks in 2024 ↗

January 08, 2024

This could be the year that psychedelics stocks start to fly.

Via The Motley Fool

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD ↗

January 06, 2024

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub

Via Benzinga

Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research ↗

January 05, 2024

Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models

Via Benzinga

AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect ↗

January 03, 2024

The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for...

Via Benzinga

Psychedelic Stock Gainers And Losers From January 1, 2024 ↗

January 01, 2024

Via Benzinga

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.